{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:29:17Z","timestamp":1770902957215,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6917","license":[{"start":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T00:00:00Z","timestamp":1040256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T00:00:00Z","timestamp":1040256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T00:00:00Z","timestamp":1040256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T00:00:00Z","timestamp":1040256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2002,12,19]]},"DOI":"10.1038\/nature01325","type":"journal-article","created":{"date-parts":[[2002,12,18]],"date-time":"2002-12-18T19:00:56Z","timestamp":1040238056000},"page":"879-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Inflammation and therapeutic vaccination in CNS diseases"],"prefix":"10.1038","volume":"420","author":[{"given":"Howard L.","family":"Weiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J.","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnature01325_CR1","first-page":"223","volume-title":"Handbook of Multiple Sclerosis","author":"JW Prineas","year":"1996","unstructured":"Prineas, J. W. in Handbook of Multiple Sclerosis (ed. Cook, S. D.) 223\u2013255 (Marcel Dekker, Newark NJ, 1996)."},{"key":"BFnature01325_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/brain\/121.1.3","volume":"121","author":"DH Miller","year":"1998","unstructured":"Miller, D. H., Grossman, R. I., Reingold, S. C. & McFarland, H. F. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121, 3\u201324 (1998).","journal-title":"Brain"},{"key":"BFnature01325_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0165-5728(99)00273-8","volume":"104","author":"HL Weiner","year":"2000","unstructured":"Weiner, H. L. et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J. Neuroimmunol. 104, 164\u2013173 (2000).","journal-title":"J. Neuroimmunol."},{"key":"BFnature01325_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.410370404","volume":"37","author":"B Cannella","year":"1995","unstructured":"Cannella, B. & Raine, C. S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37, 424\u2013435 (1995).","journal-title":"Ann. Neurol."},{"key":"BFnature01325_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1172\/JCI5150","volume":"103","author":"TL Sorensen","year":"1999","unstructured":"Sorensen, T. L. et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103, 807\u2013815 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnature01325_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/00005072-199612000-00002","volume":"55","author":"ML Cuzner","year":"1996","unstructured":"Cuzner, M. L. et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55, 1194\u20131204 (1996).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnature01325_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/S0317167100033680","volume":"25","author":"HL Weiner","year":"1998","unstructured":"Weiner, H. L. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can. J. Neurolog. Sci. 25, 93\u2013101 (1998).","journal-title":"Can. J. Neurolog. Sci."},{"key":"BFnature01325_CR8","first-page":"97","volume-title":"Handbook of Multiple Sclerosis","author":"SD Cook","year":"1996","unstructured":"Cook, S. D., Rohowsky-Kochan, C., Bansil, S. & Dowling, P. C. in Handbook of Multiple Sclerosis (ed. Cook, S. D.) 97\u2013118 (Marcel Dekker, Newark, NJ, 1996)."},{"key":"BFnature01325_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(85)92801-6","volume":"1","author":"WA Sibley","year":"1985","unstructured":"Sibley, W. A., Bamford, C. R. & Clark, K. Clinical viral infections and multiple sclerosis. Lancet 1, 1313\u20131315 (1985).","journal-title":"Lancet"},{"key":"BFnature01325_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","volume":"62","author":"G Edan","year":"1997","unstructured":"Edan, G. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiat. 62, 112\u2013118 (1997).","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"BFnature01325_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0165-5728(99)00039-9","volume":"99","author":"MI Gobbini","year":"1999","unstructured":"Gobbini, M. I., Smith, M. E., Richert, N. D., Frank, J. A. & McFarland, H. F. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroimmunol. 99, 142\u2013149 (1999).","journal-title":"J. Neuroimmunol."},{"key":"BFnature01325_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1191\/1352458502ms790oa","volume":"8","author":"HL Weiner","year":"2002","unstructured":"Weiner, H. L. & Cohen, J. A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8, 142\u2013154 (2002).","journal-title":"Mult. Scler."},{"key":"BFnature01325_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin, D. S. et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169\u2013178 (2002).","journal-title":"Neurology"},{"key":"BFnature01325_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","volume":"17","author":"TR Mosmann","year":"1996","unstructured":"Mosmann, T. R. & Sad, S. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 17, 138\u2013146 (1996).","journal-title":"Immunol. Today"},{"key":"BFnature01325_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni0901-816","volume":"2","author":"KJ Maloy","year":"2001","unstructured":"Maloy, K. J. & Powrie, F. Regulatory T cells in the control of immune pathology. Nature Immunol. 2, 816\u2013822 (2001).","journal-title":"Nature Immunol."},{"key":"BFnature01325_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1034\/j.1600-065X.2001.1820117.x","volume":"182","author":"HL Weiner","year":"2001","unstructured":"Weiner, H. L. Induction and mechanism of action of transforming growth factor-\u03b2-secreting Th3 regulatory cells. Immunol. Rev. 182, 207\u2013214 (2001).","journal-title":"Immunol. Rev."},{"key":"BFnature01325_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/39614","volume":"389","author":"H Groux","year":"1997","unstructured":"Groux, H. et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737\u2013742 (1997).","journal-title":"Nature"},{"key":"BFnature01325_CR18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor \u03b1-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151\u20131164. (1995).","journal-title":"J. Immunol."},{"key":"BFnature01325_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","volume":"80","author":"KW Wucherpfennig","year":"1995","unstructured":"Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695\u2013705 (1995).","journal-title":"Cell"},{"key":"BFnature01325_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(87)92863-7","volume":"1","author":"HS Panitch","year":"1987","unstructured":"Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1, 893\u2013895 (1987).","journal-title":"Lancet"},{"key":"BFnature01325_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1073\/pnas.94.2.599","volume":"94","author":"KE Balashov","year":"1997","unstructured":"Balashov, K. E., Smith, D. R., Khoury, S. J., Hafler, D. A. & Weiner, H. L. Increased IL-12 production in progressive multiple sclerosis: induction by activated CD4+ T-cells via CD40 ligand. Proc. Natl Acad. Sci. USA 94, 599\u2013603 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR22","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1084\/jem.182.6.1985","volume":"182","author":"A Windhagen","year":"1995","unstructured":"Windhagen, A. et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182, 1985\u20131996 (1995).","journal-title":"J. Exp. Med."},{"key":"BFnature01325_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0165-5728(02)00018-8","volume":"125","author":"A Karni","year":"2002","unstructured":"Karni, A., Koldzic, D. N., Bharanidharan, P., Khoury, S. J. & Weiner, H. L. IL-18 is linked to raised IFN-\u03b3 in multiple sclerosis and is induced by activated CD4+ T cells via CD40\u2013CD40 ligand interactions. J. Neuroimmunol. 125, 134\u2013140 (2002).","journal-title":"J. Neuroimmunol."},{"key":"BFnature01325_CR24","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1073\/pnas.96.12.6873","volume":"96","author":"KE Balashov","year":"1999","unstructured":"Balashov, K. E., Rottman, J. B., Weiner, H. L. & Hancock, W. W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1\u03b1 and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acad. Sci. USA 96, 6873\u20136878 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0165-5728(01)00371-X","volume":"119","author":"K Makhlouf","year":"2001","unstructured":"Makhlouf, K., Weiner, H. L. & Khoury, S. J. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J. Neuroimmunol. 119, 145\u2013149 (2001).","journal-title":"J. Neuroimmunol."},{"key":"BFnature01325_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1172\/JCI3125","volume":"102","author":"M Comabella","year":"1998","unstructured":"Comabella, M. et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102, 671\u2013678 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnature01325_CR27","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1126\/science.1062960","volume":"294","author":"D Chabas","year":"2001","unstructured":"Chabas, D. et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731\u20131735 (2001).","journal-title":"Science"},{"key":"BFnature01325_CR28","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.4049\/jimmunol.168.5.2096","volume":"168","author":"M Jansson","year":"2002","unstructured":"Jansson, M., Panoutsakopoulou, V., Baker, J., Klein, L. & Cantor, H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1\/osteopontin-deficient mice. J. Immunol. 168, 2096\u20132099 (2002).","journal-title":"J. Immunol."},{"key":"BFnature01325_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999).","journal-title":"Nature"},{"key":"BFnature01325_CR30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F. et al. Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916\u2013919 (2000).","journal-title":"Nature Med."},{"key":"BFnature01325_CR31","doi-asserted-by":"publisher","first-page":"10873","DOI":"10.1073\/pnas.94.20.10873","volume":"94","author":"KJ Becker","year":"1997","unstructured":"Becker, K. J. et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc. Natl Acad. Sci. USA 94, 10873\u201310878 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/4734","volume":"5","author":"G Moalem","year":"1999","unstructured":"Moalem, G. et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nature Med. 5, 49\u201355 (1999).","journal-title":"Nature Med."},{"key":"BFnature01325_CR33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1212\/WNL.56.6.702","volume":"56","author":"O Neuhaus","year":"2001","unstructured":"Neuhaus, O., Farina, C., Wekerle, H. & Hohlfeld, R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56, 702\u2013708 (2001).","journal-title":"Neurology"},{"key":"BFnature01325_CR34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI114800","volume":"86","author":"T Olsson","year":"1990","unstructured":"Olsson, T. et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-\u03b3. J. Clin. Invest. 86, 981\u2013985 (1990).","journal-title":"J. Clin. Invest."},{"key":"BFnature01325_CR35","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.179.3.973","volume":"179","author":"J Zhang","year":"1993","unstructured":"Zhang, J. et al. Increased frequency of IL-2 responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973\u2013984 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnature01325_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/358155a0","volume":"358","author":"P Lehmann","year":"1992","unstructured":"Lehmann, P., Forsthuber, T., Miller, A. & Sercarz, E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155\u2013157 (1992).","journal-title":"Nature"},{"key":"BFnature01325_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1084\/jem.174.4.791","volume":"174","author":"A Miller","year":"1991","unstructured":"Miller, A., Lider, O. & Weiner, H. L. Antigen-driven bystander suppression following oral administration of antigens. J. Exp. Med. 174, 791\u2013798 (1991).","journal-title":"J. Exp. Med."},{"key":"BFnature01325_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.186.2.307","volume":"186","author":"JJ Lafaille","year":"1997","unstructured":"Lafaille, J. J. et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186, 307\u2013312 (1997).","journal-title":"J. Exp. Med."},{"key":"BFnature01325_CR39","first-page":"621","volume-title":"Multiple Sclerosis: Pathology, Diagnosis and Management","author":"JS Romine","year":"1983","unstructured":"Romine, J. S. & Salk, J. in Multiple Sclerosis: Pathology, Diagnosis and Management (eds Hallpike, J. F., Adams, C. M. W. & Tourtelotte, W. W.) 621\u2013630 (Williams & Wilkins, Baltimore, 1983)."},{"key":"BFnature01325_CR40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/80516","volume":"6","author":"B Bielekova","year":"2000","unstructured":"Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83\u201399) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167\u20131175 (2000).","journal-title":"Nature Med."},{"key":"BFnature01325_CR41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/80525","volume":"6","author":"L Kappos","year":"2000","unstructured":"Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nature Med. 6, 1176\u20131182 (2000).","journal-title":"Nature Med."},{"key":"BFnature01325_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1471-4906(01)02020-8","volume":"22","author":"V Kumar","year":"2001","unstructured":"Kumar, V., Sercarz, E., Zhang, J. & Cohen, I. T-cell vaccination: from basics to the clinic. Trends Immunol. 22, 539\u2013540 (2001).","journal-title":"Trends Immunol."},{"key":"BFnature01325_CR43","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1023\/A:1010951706830","volume":"26","author":"AA Vandenbark","year":"2001","unstructured":"Vandenbark, A. A. et al. TCR peptide therapy in human autoimmune diseases. Neurochem. Res. 26, 713\u2013730 (2001).","journal-title":"Neurochem. Res."},{"key":"BFnature01325_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(95)91622-9","volume":"346","author":"R Medaer","year":"1995","unstructured":"Medaer, R., Stinissen, P., Truyen, L., Raus, J. & Zhang, J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 346, 807\u2013808 (1995).","journal-title":"Lancet"},{"key":"BFnature01325_CR45","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1073\/pnas.030390097","volume":"97","author":"R Weissert","year":"2000","unstructured":"Weissert, R. et al. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc. Natl Acad. Sci. USA 97, 1689\u20131694 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1172\/JCI8759","volume":"106","author":"G Wildbaum","year":"2000","unstructured":"Wildbaum, G., Westermann, J., Maor, G. & Karin, N. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J. Clin. Invest. 106, 671\u2013679 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnature01325_CR47","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.4049\/jimmunol.168.11.5885","volume":"168","author":"G Wildbaum","year":"2002","unstructured":"Wildbaum, G., Netzer, N. & Karin, N. Plasmid DNA encoding IFN-\u03b3-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 168, 5885\u20135892 (2002).","journal-title":"J. Immunol."},{"key":"BFnature01325_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1074-7613(01)00171-6","volume":"15","author":"H Garren","year":"2001","unstructured":"Garren, H. et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15, 15\u201322 (2001).","journal-title":"Immunity"},{"key":"BFnature01325_CR49","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe, D. J. Alzheimer's disease: genes, proteins and therapies. Physiol. Rev. 81, 742\u2013761 (2001).","journal-title":"Physiol. Rev."},{"key":"BFnature01325_CR50","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383\u2013421 (2000).","journal-title":"Neurobiol. Aging"},{"key":"BFnature01325_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0197-4580(00)00148-2","volume":"21","author":"NR Cooper","year":"2000","unstructured":"Cooper, N. R., Kalaria, R. N., McGeer, P. L. & Rogers, J. Key issues in Alzheimer's disease inflammation. Neurobiol. Aging 21, 451\u2013453 (2000).","journal-title":"Neurobiol. Aging"},{"key":"BFnature01325_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0531-5565(98)00013-8","volume":"33","author":"EG McGeer","year":"1998","unstructured":"McGeer, E. G. & McGeer, P. L. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33, 371\u2013378 (1998).","journal-title":"Exp. Gerontol."},{"key":"BFnature01325_CR53","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/S0197-4580(98)00036-0","volume":"19","author":"J El Khoury","year":"1998","unstructured":"El Khoury, J., Hickman, S. E., Thomas, C. A., Loike, J. D. & Silverstein, S. C. Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease. Neurobiol. Aging 19, S81\u2013S84 (1998).","journal-title":"Neurobiol. Aging"},{"key":"BFnature01325_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/374647a0","volume":"374","author":"L Meda","year":"1995","unstructured":"Meda, L. et al. Activation of microglial cells by \u03b2-amyloid protein and interferon-\u03b3. Nature 374, 647\u2013650 (1995).","journal-title":"Nature"},{"key":"BFnature01325_CR55","doi-asserted-by":"publisher","first-page":"10837","DOI":"10.1073\/pnas.162350199","volume":"99","author":"T Wyss-Coray","year":"2002","unstructured":"Wyss-Coray, T. et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl Acad. Sci. USA 99, 10837\u201310842 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W","volume":"48","author":"HL Weiner","year":"2000","unstructured":"Weiner, H. L. et al. Nasal administration of amyloid-\u03b2 peptide decreases cerebral amyloid burden in mouse model of Alzheimer's disease. Ann. Neurol. 48, 567\u2013579 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnature01325_CR57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain A\u03b2 burden in Alzheimer's disease model. Nature Neurosci. 5, 452\u2013457 (2002).","journal-title":"Nature Neurosci."},{"key":"BFnature01325_CR58","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos, R. B. et al. Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850\u20138855 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR59","unstructured":"Schenk, D. in Immunization against Alzheimer's Disease and Other Neurodegenerative Disorders (eds Selkoe, D. & Christen, Y.) (Springer, Heidelberg, in the press)."},{"key":"BFnature01325_CR60","unstructured":"Furlan, R. et al. Vaccination with amyloid-\u03b2 peptide induces autoimmune encephalomyelitis in C57BL\/6 mice. Brain (in the press)."},{"key":"BFnature01325_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0165-5728(92)90136-9","volume":"40","author":"C Linington","year":"1992","unstructured":"Linington, C., Engelhardt, B., Kapocs, G. & Lassman, H. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J. Neuroimmunol. 40, 219\u2013224 (1992).","journal-title":"J. Neuroimmunol."},{"key":"BFnature01325_CR62","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"11","author":"J McLaurin","year":"2002","unstructured":"McLaurin, J. et al. Therapeutically effective antibodies against amyloid-\u03b2 peptide target amyloid-\u03b2 residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis. Nature Med. 11, 1263\u20131269 (2002).","journal-title":"Nature Med."},{"key":"BFnature01325_CR63","doi-asserted-by":"publisher","first-page":"10273","DOI":"10.1073\/pnas.191118298","volume":"98","author":"A Monsonego","year":"2001","unstructured":"Monsonego, A., Maron, R., Zota, V., Selkoe, D. J. & Weiner, H. L. Immune hyporesponsiveness to amyloid \u03b2-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 10273\u201310278 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature01325_CR64","doi-asserted-by":"crossref","unstructured":"Monsonego, A. et al. Immunogenic aspects of amyloid \u03b2-peptide: implications for pathogenesis and treatment of Alzheimer's disease. Abstr. no. 423 in Proc. VIII Int. Conf. on Alzheimer's Disease and Related Disorders, Stockholm, Sweden (2002).","DOI":"10.1007\/978-3-642-59332-1_1"},{"key":"BFnature01325_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/0197-4580(96)00068-1","volume":"17","author":"K Trieb","year":"1996","unstructured":"Trieb, K., Ransmayr, G., Sgonc, R., Lassmann, H. & Grubeck-Loebenstein, B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging 17, 541\u2013547 (1996).","journal-title":"Neurobiol. Aging"},{"key":"BFnature01325_CR66","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/intimm\/11.9.1573","volume":"11","author":"R Maron","year":"1999","unstructured":"Maron, R. et al. Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int. Immunol. 11, 1573\u20131580 (1999).","journal-title":"Int. Immunol."},{"key":"BFnature01325_CR67","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/87945","volume":"7","author":"T Wyss-Coray","year":"2001","unstructured":"Wyss-Coray, T. et al. TGF-\u03b21 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612\u2013618 (2001).","journal-title":"Nature Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature01325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature01325","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature01325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T19:59:40Z","timestamp":1743796780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature01325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,19]]},"references-count":67,"journal-issue":{"issue":"6917","published-print":{"date-parts":[[2002,12,19]]}},"alternative-id":["BFnature01325"],"URL":"https:\/\/doi.org\/10.1038\/nature01325","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12,19]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}